Your search history is turned on.
Date: February 3, 2023 Jurisdictions: Alberta, British Columbia
Bioasis Announces AGM Results and Provides Update on Financial Position NEW HAVEN, Conn., Feb. 03, 2023 -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 platform for delivering therapeutics across the b...
Date: February 1, 2023 Jurisdictions: Alberta, British Columbia
FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Bioasis Technologies Inc. (the Company or Bioasis) 157 Church Street New Haven, Connecticut 06510 Item 2. Date of Material Change January 23, 2023 Item 3. News Release Attached as Schedule A is a copy of a press...
Date: January 23, 2023 Jurisdictions: Alberta, British Columbia
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc NEW HAVEN, Conn., Jan. 23, 2023 -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 platform for delive...
Date: January 19, 2023 Jurisdictions: Alberta, British Columbia
Microsoft Word - Bioasis_52-109FV2_CFO Cert Q3 FY23 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, David P. Jenkins, Chief Financial Officer of Bioasis Technologies Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Bioasis T...
Microsoft Word - Bioasis_52-109FV2_CEO Cert Q3 FY23 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Deborah Rathjen, Chief Executive Officer of Bioasis Technologies Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Bioasis Te...
Bioasis Technologies Inc. Managements Discussion and Analysis 1 Managements Discussion and Analysis For the Three and Nine Months Ended November 30, 2022 and 2021 Dated: January 19, 2023 157 Church Street, 19th Floor New Haven, CT 06510...
Microsoft Word - BTI Q3 FY'23 (Nov'22) FS Report BIOASIS TECHNOLOGIES INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Expressed in Canadian dollars) (Unaudited) For the Three and Nine Months Ended November 30, 2022 and 2021 1 ...
Source: Bioasis Technologies Inc. January 19, 2023 17:05 ET Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022 NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis), a multi-asset rare and orphan disease biopharmaceutical company devel...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022 NEW HAVEN, Conn., Jan. 19, 2023 -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 platf...
Date: January 11, 2023 Jurisdictions: Alberta, British Columbia
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSU...